Kane Biotech Appoints Dr. Sarah Prichard, M.D. to the Board of Directors
April 2, 2014 (Source: Marketwired) — Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms announces today the appointment of Dr. Sarah Prichard, M.D. FRCP(C) to its board of directors.
Dr. Prichard has served as global Vice President of R&D, Renal Medical and Therapeutic Area Leader, Baxter Healthcare from 2005-2014. Prior to this role, she was on faculty at McGill University from 1979-2005.
Dr. Prichard received her MD from Queens University and trained in Internal Medicine and Nephrology at McGill University. While at McGill, she served as Associate Dean of Medicine, Chief of Service for the Department of Medicine, Senior Physician and Director of Peritoneal Dialysis at the Royal Victoria Hospital. She was the President of the Canadian Society of Nephrology (1997-2000) and President of the International Society of Peritoneal Dialysis (2001-2004). During her academic career, she published extensively in the area of dialysis, lectured around the globe and received the Osler Award for teaching.
Sarah has also played leadership roles as a member of the Board of Queens University, Chair of the Board of St. Mary’s Hospital Center in Montreal and a member of the Governing Council of CIHR (Canadian Institute of Health Research).
Her current interests are in product innovation, market access and global health policies.
“On behalf of the board of directors and the management and staff of Kane Biotech, I am pleased to welcome Sarah as a director. We look forward to the insight, guidance and expertise that she will bring to the Company,” stated Gord Froehlich, President and CEO of Kane Biotech Inc.
Get our daily investorintel update
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane’s early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane’s filings with Canadian securities regulatory authorities, as well as Kane’s ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane’s forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks of Kane Biotech Inc. All Rights Reserved 2014.
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.